UY32605A - Agentes antiinflamatorios como compuestos virostáticos - Google Patents
Agentes antiinflamatorios como compuestos virostáticosInfo
- Publication number
- UY32605A UY32605A UY0001032605A UY32605A UY32605A UY 32605 A UY32605 A UY 32605A UY 0001032605 A UY0001032605 A UY 0001032605A UY 32605 A UY32605 A UY 32605A UY 32605 A UY32605 A UY 32605A
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- virostatic
- inflammatory agents
- medicaments
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuestos de la fórmula general (I) y sus sales y derivados funcionales desde el punto de vista fisiológico que pueden usarse como medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17525509P | 2009-05-04 | 2009-05-04 | |
EP09159358 | 2009-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32605A true UY32605A (es) | 2010-12-31 |
Family
ID=43030861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032605A UY32605A (es) | 2009-05-04 | 2010-05-03 | Agentes antiinflamatorios como compuestos virostáticos |
Country Status (16)
Country | Link |
---|---|
US (1) | US8354433B2 (es) |
EP (1) | EP2427186B1 (es) |
CN (1) | CN102458389A (es) |
AR (1) | AR076837A1 (es) |
AU (1) | AU2010244462B2 (es) |
CA (1) | CA2761130C (es) |
CO (1) | CO6450622A2 (es) |
ES (1) | ES2909738T3 (es) |
MX (1) | MX2011011733A (es) |
NZ (1) | NZ596014A (es) |
PE (1) | PE20120898A1 (es) |
SG (1) | SG175854A1 (es) |
TW (1) | TWI530286B (es) |
UY (1) | UY32605A (es) |
WO (1) | WO2010128050A2 (es) |
ZA (1) | ZA201108131B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA108760C2 (uk) * | 2010-07-01 | 2015-06-10 | Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби | |
WO2013009678A2 (en) * | 2011-07-08 | 2013-01-17 | Indiana University Research And Technology Corporation | Compositions and methods for the treatment of norovirus infection |
RU2016144238A (ru) * | 2014-04-11 | 2018-05-11 | Паноптес Фарма Гмбх | Противовоспалительные средства в качестве вирусостатических соединений |
SG11201608835VA (en) * | 2014-05-08 | 2016-11-29 | Panoptes Pharma Ges M B H | Compounds for treating ophthalmic diseases and disorders |
TW201834649A (zh) | 2017-03-02 | 2018-10-01 | 新加坡商亞獅康私人有限公司 | 癌症療法 |
WO2020225330A1 (en) * | 2019-05-07 | 2020-11-12 | Universität Hamburg | Dhodh inhibitors and their use as antiviral agents |
KR20230004636A (ko) * | 2020-04-21 | 2023-01-06 | 이뮤닉 아게 | 바이러스성 질환의 치료 또는 예방에서 사용하기 위한 비도플루디무스 |
WO2022045984A1 (en) * | 2020-08-31 | 2022-03-03 | Aslan Pharmaceuticals Pte Ltd | Treatment and/or prevention of a viral infection |
WO2022196236A1 (ja) * | 2021-03-18 | 2022-09-22 | 国立大学法人 鹿児島大学 | 抗薬剤耐性インフルエンザウイルス剤及び抗薬剤耐性インフルエンザウイルス剤の製造のための化合物の使用 |
EP4320100A1 (en) | 2021-04-09 | 2024-02-14 | Immunic AG | Deuterated dhodh inhibitors |
EP4119138A1 (en) * | 2021-07-12 | 2023-01-18 | Universität Hamburg | Dhodh inhibitors and their use as antiviral agents |
TW202332433A (zh) | 2021-12-23 | 2023-08-16 | 德商埃慕尼克股份公司 | 含羧酸生物電子等排體之dhodh抑制劑 |
US20230278979A1 (en) * | 2022-03-01 | 2023-09-07 | Kiora Pharmaceuticals Gmbh | Salts of a dihydroorotate dehydrogenase (dhod) inhibitor |
WO2023172818A1 (en) * | 2022-03-09 | 2023-09-14 | Kiora Pharmaceuticals Gmbh | Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor |
WO2023232884A1 (en) | 2022-06-01 | 2023-12-07 | Immunic Ag | Treatment of ulcerative colitis comprising vidofludimus or a pharmaceutically acceptable salt thereof |
CN116803387A (zh) * | 2023-07-25 | 2023-09-26 | 徐州医科大学 | Vidofludimus在制备戊型肝炎药物中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19860802A1 (de) * | 1998-12-30 | 2000-10-26 | Virgene Pharmaceuticals Ag | Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren |
AU7622000A (en) * | 1999-10-01 | 2001-05-10 | Institute Of Molecular And Cell Biology | Compounds for the treatment of viral-mediated diseases |
MXPA04000224A (es) * | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
JP2006514023A (ja) * | 2002-12-23 | 2006-04-27 | 4エスシー エージー | 抗炎症剤、免疫調節剤及び増殖抑制剤としての芳香族化合物 |
AU2003300530A1 (en) * | 2002-12-23 | 2004-07-14 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
US7071355B2 (en) * | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
-
2010
- 2010-04-30 TW TW099113936A patent/TWI530286B/zh not_active IP Right Cessation
- 2010-05-03 UY UY0001032605A patent/UY32605A/es not_active Application Discontinuation
- 2010-05-03 US US12/772,470 patent/US8354433B2/en active Active
- 2010-05-04 ES ES10715894T patent/ES2909738T3/es active Active
- 2010-05-04 CN CN2010800290606A patent/CN102458389A/zh active Pending
- 2010-05-04 WO PCT/EP2010/056042 patent/WO2010128050A2/en active Application Filing
- 2010-05-04 SG SG2011080488A patent/SG175854A1/en unknown
- 2010-05-04 AR ARP100101509A patent/AR076837A1/es unknown
- 2010-05-04 AU AU2010244462A patent/AU2010244462B2/en not_active Ceased
- 2010-05-04 EP EP10715894.1A patent/EP2427186B1/en active Active
- 2010-05-04 NZ NZ596014A patent/NZ596014A/xx not_active IP Right Cessation
- 2010-05-04 PE PE2011001900A patent/PE20120898A1/es not_active Application Discontinuation
- 2010-05-04 MX MX2011011733A patent/MX2011011733A/es active IP Right Grant
- 2010-05-04 CA CA2761130A patent/CA2761130C/en not_active Expired - Fee Related
-
2011
- 2011-11-03 ZA ZA2011/08131A patent/ZA201108131B/en unknown
- 2011-11-04 CO CO11150236A patent/CO6450622A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2761130A1 (en) | 2010-11-11 |
CO6450622A2 (es) | 2012-05-31 |
PE20120898A1 (es) | 2012-08-24 |
WO2010128050A2 (en) | 2010-11-11 |
ZA201108131B (en) | 2012-07-25 |
MX2011011733A (es) | 2012-02-01 |
WO2010128050A3 (en) | 2011-05-05 |
AU2010244462A1 (en) | 2011-11-17 |
AR076837A1 (es) | 2011-07-13 |
ES2909738T3 (es) | 2022-05-10 |
EP2427186A2 (en) | 2012-03-14 |
CN102458389A (zh) | 2012-05-16 |
CA2761130C (en) | 2017-03-28 |
AU2010244462B2 (en) | 2015-07-02 |
TW201043228A (en) | 2010-12-16 |
TWI530286B (zh) | 2016-04-21 |
SG175854A1 (en) | 2011-12-29 |
EP2427186B1 (en) | 2022-01-12 |
US20100280081A1 (en) | 2010-11-04 |
NZ596014A (en) | 2013-06-28 |
US8354433B2 (en) | 2013-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32605A (es) | Agentes antiinflamatorios como compuestos virostáticos | |
GT201000023A (es) | Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met. | |
CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
ECSP088666A (es) | Derivados de las benzamidas y heteroarenos | |
UY31001A1 (es) | Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas | |
CO6400220A2 (es) | Derivados de sulfonamida | |
CO6670585A2 (es) | Promotores de apotosis n-acilsufonamidas | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
CO6491082A2 (es) | Derivados de n 1-sulfonil-5-fluoropirimidinona | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
CL2008003690A1 (es) | Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos. | |
CR20110407A (es) | Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
SV2010003514A (es) | Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
HN2011001019A (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) produccion y uso de los mismos como productos medicinales | |
CR20110219A (es) | Ácidos naftilacéticos | |
CR10963A (es) | Compuestos de 2-amino pirimidina | |
CR20110269A (es) | Lactamas como inhibidores de beta secretasa | |
CO6741154A2 (es) | Compuestos de triazolopiridina | |
SV2010003752A (es) | Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas | |
CR20110680A (es) | Sulfonamidas heterociclicas, usos y composiciones farmacéuticas de las mismas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20181127 |